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Context: Antithyroid drug (ATD) therapy in early pregnancy is associated with birth defects, but 
more data are needed to substantiate the risk associ ted with different types of ATD. 
Furthermore, the role of abnormal maternal thyroid function per se remains unclarified. 
Objective: To evaluate the risk of birth defects associated with the use of ATD in an extended 
nationwide cohort and the role of abnormal maternal thyroid function in birth cohorts including 
stored maternal blood samples from the early pregnancy.  
Participants: Danish pregnant women and their live-born children including 1,242,353 children 
from a Nationwide Register-Based Cohort (NRBC), 1997-2016; 8,803 children from the Danish 
National Birth Cohort (DNBC), 1997-2003; and 14,483 children from the North Denmark 
Region Pregnancy Cohort (NDRPC), 2011-2015. 
Main outcome measures: Birth defects diagnosed before two years of age. 
Results: In the NRBC, altogether 2,718 (0.2%) children had been exposed to ATD in early 
pregnancy. The overall frequency of birth defects wa  6.7% (95% confidence interval (CI): 6.7-
6.8%) in non-exposed children, and higher after exposure to Methimazole/Carbimazole (9.6% 
(95% CI: 8.2-11.2%)) and Propylthiouracil (8.3% (6.7-10.3%). On the other hand, the frequency 
of maternal thyroid dysfunction in early pregnancy was similar in the random cohort and in cases 
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Conclusions: Results corroborate an increased risk of birth defects associated with the use of 
ATD in early pregnancy, and suggest that abnormal maternal thyroid function is not a major risk 
factor for birth defects.  
The risk of birth defects after early pregnancy exposure to antithyroid drugs and abnormal maternal 
thyroid function was evaluated in a Danish nationwide register-based cohort and in birth cohorts. . 
Introduction 
Antithyroid drug (ATD) is preferred for the treatment of hyperthyroidism in pregnancy (1,2). 
The hyperthyroidism of Graves’ disease (GD) in pregnant women should be treated to prevent 
maternal and fetal complications, but raises a concern regarding the risk of birth defects 
associated with the use of ATD (3). An  embryopathy of specific, severe birth defects associated 
with the use of Methimazole (MMI) and Carbimazole (CMZ) has been known for years, but 
analytical observational studies were not reported until a decade ago (4). These findings have 
challenged and re-phrased the clinical guidance for the management of hyperthyroidism in 
pregnant women, because birth defects have been associ ted with MMI/CMZ, and also with 
PTU (5). Thus, a clinical focus on balancing the ned for treatment against the potential 
teratogenic side effects has been introduced in revised clinical guidance, although the evidence 
regarding ATD withdrawal in early pregnancy is at present inadequate (1,2).  An increased risk 
of birth defects associated with the use of MMI/CMZ has been consistently described (6–8). On 
the other hand, human observational as well as experimental animal studies have shown 
divergent results considering the risk of birth defects after exposure to PTU (6–11). Uncertainty 
remains regarding the risk of birth defects associated with the different types of ATD, and more 
data are needed.  
We previously evaluated the risk of birth defects in a nationwide study of all children in 
Denmark born from 1996 to 2008 (7). We now extended th  cohort and included children born 
during the 20-year period from 1997 to 2016. Furthermore, we measured maternal thyroid 
function in stored blood samples from pregnant women who were part of different birth cohorts 
in Denmark in the years 1997-2003 and 2011-2015. This allowed for the evaluation of the 
unresolved role of maternal thyroid function per se in the development of birth defects. 
Materials and methods 
Study population 
The study included a Nationwide Register-Based Cohort (NRBC), participants from the Danish 
National Birth Cohort (DNBC) and participants from the North Denmark Region Pregnancy 
Cohort (NDRPC). The NRBC included all children live-born in Denmark from January 1, 1997 
to December 31, 2016 who were identified in the Danish Medical Birth Register (MBR) (12) and 
had available information on gestational age at birth (Figure 1). The registration procedure in the 
MBR was changed from January 1, 1997 and only children born from 1997 and onwards were 
included in the present study to ensure similar registrations throughout the study period. The 
NRBC was used to evaluate the association between maternal use of ATD and birth defects, but 
no information on biochemical measurements were available in the register-based cohort.  
The DNBC and the NDRPC included the measurement of maternal thyroid function in a 
stored blood sample from the early pregnancy, and these cohorts were used to evaluate the 
association between abnormal maternal thyroid functio  and birth defects. The DNBC was 
established from 1997-2003 and included 77,671 children live-born in Denmark (Figure 1). For 
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cohort (n=7,624) and/or because their child was diagnosed with birth defects within two years of 
follow-up (n=1,383). The NDRPC was established from 2011-2015. It included all pregnant 
women in the North Denmark Region who had a blood sample drawn in early pregnancy as part 
of prenatal screening for chromosomal anomalies and women who gave birth to a singleton live-
born children were included in the study (Figure 1). 
The study and the data handling were approved by the Danish data protection Agency (J.nr. 
2008-58-0028). Furthermore, the biochemical measurements in stored blood samples was 
approved by the North Denmark Region Committee on Health Research Ethics (N-20130054 and 
N-20150015).  
Exposure definitions 
In the NRBC, the exposure of main interest was the use of ATD in early pregnancy, which was 
assessed from redeemed prescriptions of the drugs in the period ranging from six months prior to 
pregnancy start up to and including the 10th week of pregnancy, as described previously in detail 
(7). The Danish National Prescription Register (DNPR) (13) includes information on redeemed 
prescriptions of drugs coded according to the Anatomical Therapeutical Classification (ATC) 
system, and drugs used for the treatment of thyroid disease are included in the ATC group: H03. 
The latest redeemed prescription prior to pregnancy start (or the first in pregnancy if no previous 
treatment) was used to determine the exposure status in he early pregnancy, and women who 
redeemed both  MMI/CMZ and PTU after pregnancy start we e grouped separately and 
considered ‘double’ exposed. CMZ is a prodrug to MMI and was combined with MMI and 
described as MMI exposure in the present study. The non-exposed group was defined as children 
whose mother had no diagnosis of hyperthyroidism, no registration of thyroid surgery and no 
redeemed prescription of ATD or Levothyroxine befor, during or after the pregnancy under 
study and up to December 31, 2017.   
In the DNBC and NDRPC, the exposure of interest was abnormal maternal thyroid function, 
which was assessed from the measurement of TSH and free T4 (fT4) in a stored blood sample 
from the early pregnancy (median week 9-10), as described previously in detail (14,15). Thyroid 
function parameters were measured using a Dimension Vista (Siemens Healthineers, Germany) 
immunoassay in the DNBC and an Advia Centaur (Siemens Healthineers, Germany) 
immunoassay in the NDRPC. In both cohorts, pregnancy week specific reference ranges had 
been established (14,15) and were used for the classific tion of maternal thyroid function as 
normal (euthyroid) or abnormal (overt and subclinical hyper- and hypothyroidism as well as 
isolated low and high fT4).  
Outcome assessment 
Information on birth defects in the child was assesed from in- and outpatient hospital diagnoses 
in the Danish National Hospital Register (DNHR) (16) coded according to the 10th International 
Classification of Disease (ICD-10). All diagnoses of birth defects (ICD-10: Q00-Q99) diagnosed 
before the child was two years old were assessed in the NRBC and grouped in accordance with 
our previous report (7). In the DNBC, children were selected for the study if they had a 
diagnoses within the eight groups of birth defects (Q10-15 (eyes), Q18 (face and neck, others), 
Q20-28 (circulatory), Q30-38 (respiratory), Q39-45 (digestive), Q60-64 (urinary), Q79 
(musculoskeletal, others), Q80-84 (integumentary system) previously associated with the use of 






























































/advance-article-abstract/doi/10.1210/jc.2019-01343/5548919 by Aalborg U









The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-01343 
 
 4
In the NRBC, the frequency of birth defects by ATD exposure was compared using Chi-square 
test. Furthermore, we reported the results of a Cox pr portional hazards model (hazard ratio 
(HR) with 95% confidence interval (95% CI) adjusting for multiple birth, maternal age, parity, 
and smoking (from the MBR), origin (from Statistics Denmark), and diabetes (from the DNHR 
and DNPR). Information on maternal pre-pregnancy body mass index (BMI) was only available 
in the MBR from 2004 and onwards and was included in a sub-analyses. In the DNBC and 
NDRPC, the association between abnormal maternal thyroid function and birth defects was 
evaluated using a Cox proportional hazards model, which was a weighted model in the DNBC to 
account for the sampling procedure and the overlap between cases and the random sub-cohort, as 
previously described (17). The adjusted model evaluating these associations included 
information on maternal age, parity, origin, smoking, BMI, and diabetes.  
Results 
Study populations 
The extended NRBC cohort included 1,242,353 pregnancies (Figure 1 and Table 1) 
corresponding to the birth year period of the previous cohort (1997-2008) and the later cohort 
(2009-2016). The DNBC included a total of 8,803 pregnancies and 14,483 pregnancies were 
included in the NDRPC (Figure 1 and Table 1).  
The cohorts were established during a 20-year period, which introduced some differences in 
maternal characteristics (Table 1). Notably, maternal age increased over time, but was lower in 
the NDRPC compared with the national cohort around the same time, which is compatible with 
known regional differences in Denmark. The frequency of maternal smoking in pregnancy 
decreased over time, whereas the frequency of maternal diabetes and non-Danish origin 
increased.  As expected, the frequency of non-Danish origin was lower in the DNBC (Table 1) 
since one of the selection criteria in this cohort was the ability to speak Danish well enough to 
participate in a sequence of telephone interviews.  
ATD and birth defects 
Altogether 2,718 children (0.2%) had been exposed to maternal use of ATD in early pregnancy 
in the extended NRBC cohort. MMI was the most frequently used ATD both in the extended and 
in the previous cohort, and the ratio of MMI to PTU exposure was 2.0 in the previous and 1.8 in 
the extended cohort (Table 2).  
A total of 83,875 children (6.8%) were diagnosed with a birth defect before two years of age 
in the extended NRPC cohort. An increasing trend in the frequency of birth defects according to 
birth year of the child was observed throughout the study period (Figure 2), which was less 
pronounced for the specific subtypes of birth defects previously associated with the use of ATD.  
Exposure to MMI was associated with a significantly higher prevalence of birth defects, both 
when evaluating all birth defects and the defects previously associated with the use of ATD 
(Table 2). For exposure to PTU, a higher frequency of birth defects was observed in the extended 
and in the previous cohort compared with non-exposed, but the association was weakened in the 
extended cohort. Looking at subgroups of birth defects in the extended cohort (Table 3), MMI 
exposure was associated with birth defects in seven organ systems, whereas PTU revealed an 
association with face and neck defects and urinary system malformations only. 
Exposure to MMI was associated with a high risk (adjusted hazard ratio 20 (95% confidence 
interval: 12-34)) of the group of specific malformations considered part of an MMI embryopathy 
(aplasia cutis, esophageal atresia, choanal atresia, and omphalocele). A small group of children 





























































/advance-article-abstract/doi/10.1210/jc.2019-01343/5548919 by Aalborg U









The Journal of Clinical Endocrinology & Metabolism; Copyright 2019  DOI: 10.1210/jc.2019-01343 
 
 5
from MMI to PTU after pregnancy start (n=240) or from PTU to MMI (n=15). The frequency of 
the subgroups of birth defects previously associated with the use of ATD was 5.0% when the 
mother shifted to PTU after pregnancy start versus 3.1% in non-exposed (p=0.09).  
The associations between the use of ATD and birth defects were similar when the period for 
evaluation of exposure was narrowed to three months prior to pregnancy start or to the early 
pregnancy weeks. Furthermore, results did not change when the follow-up period for assessment 
of birth defects in the child was reduced to one month, one year, or extended to five year or 
complete follow-up  (median to age 11 years (range 1-21 years)). 
Maternal thyroid function and birth defects 
The association between maternal thyroid function in pregnancy and birth defects was evaluated 
in the DNBC and in the NDRPC (Table 4). The overall frequency of abnormal thyroid function 
was 12.5% in the DNBC and 15.1% in the NDRPC. In both c horts, the overall frequency of 
abnormal thyroid function did not differ between the randomly sampled cohort and cases of birth 
defects (Table 4). For subtypes of maternal thyroid dysfunction, no associations with birth 
defects were observed, except for an association with overt hypothyroidism in the DNBC.  
When considering subtypes of birth defects in children exposed to overt hypothyroidism in 
the DNBC, it appeared that this association was dominated by malformations of the eye and of 
the circulatory system, but numbers were too sparse to p rform stratified adjusted analyses.  
Results were similar when analyses were restricted to pregnancies in which the blood sample 
was drawn prior to pregnancy week 11 (n=6,715 in the DNBC; n=10,343 in the NDRPC), or to 
pregnancies in which the mother received no current t a ment with ATD or Levothyroxine at 
the time of blood sampling (n=8,791 in DNBC; n=14,290 in NDRPC). 
Discussion 
In a large extended nationwide cohort of more than one million children live-born in Denmark 
during a 20-year period, an increased risk of birth defects associated with the use of ATD in 
early pregnancy was corroborated. The sub-types of birth defects associated with the use of MMI 
and PTU differed, and MMI exposure revealed the highest risk and associations with severe birth 
defects in several organ systems. On the other hand, birth defects observed after early pregnancy 
exposure to PTU were mostly located in the urinary system and in the face and neck. The role of 
maternal thyroid function was addressed in independent birth cohorts, and results did not indicate 
that abnormalities in maternal thyroid function in early pregnancy per se is a major risk factor for 
birth defects.  
The use of ATD for the treatment of hyperthyroidism was discovered in the 1940s and still 
play a dominant role in the management of patients (18). A main concern about the use of ATD 
in non-pregnant and pregnant individuals is the risk of severe side effects, and treatment of 
pregnant women is specific for the risk of birth defects (4). Severe birth defects after the use of 
MMI in early pregnancy were described in the 1970s (19), but it was not until 2011 that the first 
observational case-control study was published (20). Since then, a series of observational studies 
have been conducted (6–8,21–24), and evidence suggets a risk of birth defects associated with 
the use of MMI, and more recently also with PTU. Nevertheless, the findings differ between 
studies and many methodological considerations are of importance when studying relatively rare 
outcomes that need to survive until birth. A notable disparity between the studies that reported an 
association and those that found no association is the number of exposed children. Thus, the 
studies that found an association with the use of MMI in early pregnancy included more than 
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in the child. Birth defects are by definition present at birth, but the defects may not be detected 
clinically at birth, and less severe malformations may be diagnosed at a later age (4).  
The present study is an extension of our previous report published in 2013, in which we 
reported that both MMI and PTU were associated withbirth defects diagnosed before the child 
was two years old in a nationwide cohort of children born in Denmark from 1996-2008 (7). The 
finding of an MMI embryopathy was consistent with case reports (25,26) and a large 
observational study from Japan published in 2012 (6), but the finding of a risk of birth defects 
associated with PTU was new and merited further investigation (27). We now had data to extend 
the cohort to include children born in Denmark during a 20-year period from 1997-2016. We 
strictly applied the same methodology regarding the definition of exposure and outcome and 
evaluated the overall prevalence of birth defects as well as subgroups of birth defects. Overall, 
results corroborated an association with MMI, but the association between maternal use of PTU 
in early pregnancy and birth defects was attenuated nd at the border of statistical significance in 
the extended cohort. This disparity in the association observed in the previous and the extended 
cohort call into question the accuracy of the previous finding and supports a focus on this 
association to settle if it was coincidental. Thus, it was an important finding that MMI and PTU 
revealed associations with the same specific subtypes of birth defects in the extended cohort as in 
the previous cohort, and the disparity between MMI and PTU for subgroups of birth defects 
prevailed. This consistency in the associations observed supports an association. For PTU, an 
association with malformations in the face and neck r gion and in the urinary system was 
observed both in the previous and in the extended cohort although no new cases of PTU 
associated malformations of the face and neck region were identified in the extended cohort, 
while two new cases of malformation of the urinary system were seen. It is important to notice 
that subtypes of malformations are rare and face and neck malformations occurred in 0.08% of 
non-exposed children. Thus, even though we extended the cohort with eight more years, the lack 
of new cases may reflect the low prevalence of these malformations. This emphasizes the 
importance of future extended follow-up. Another consideration is the registrations of birth 
defects.  If any, we would expect an increased diagnostic activity, which was apparent from the 
increase in the overall prevalence of birth defects in he extended cohort. However, for the sub-
types of birth defects previously associated with the use of ATD, the prevalence did not show a 
similar change. In addition, the clinical focus on side effects to the use of ATD brought forward 
by publications in 2012-2013 (6,7) may have influenced the awareness and the registration 
although international clinical guidance was revised in 2016-2017 (1,2), which overlaps the end 
of the study period in the extended cohort. Furthermore, only a slight change in the ratio of MMI 
to PTU exposure was observed between the previous and the extended cohort indicating no 
major change in clinical practice.  
A strength of the present study was the large extended study population, which enabled us to 
study a relatively rare exposure and outcomes. Another register-based study using Korean 
National Health Insurance databases was published in 2018 and included more than two million 
live-born children (8). Similar to our findings, both MMI and PTU exposure was associated with 
birth defects in this study, and the authors further showed a dose-dependent association with 
MMI. We did not have information on the dose of ATD in the Danish nationwide registers, and 
we do not know if the women actually took the prescibed drug, but a strength of our study was 
the detailed assessment of ATD exposure. We considered all prescriptions of ATD in the period 
before and in early pregnancy and the last redeemed prescription prior to pregnancy start defined 
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when using indirect measures of exposure from redeemed prescriptions of drugs (28). A clinical 
focus is on the timing of a shift in therapy from MMI to PTU around pregnancy start and the 
possibility of ATD withdrawal (1,2). In our previous and extended cohort and in the study from 
Korea (8), a higher risk of birth defects was observed in women who shifted from MMI to PTU 
treatment after pregnancy start. We previously evaluated these cases in detail and although the 
number of exposed cases was limited, this evaluation sh wed that the timing of a shift in therapy 
may be important to reduce MMI exposure (29). Further studies are needed to evaluate the 
outcomes of birth defects in women who shifted from MMI to PTU before or during the early 
pregnancy period as well as the outcomes of ATD withdrawal in early pregnancy, and large 
study populations are required to obtain a sufficient number of exposed cases.     
The role of maternal thyroid function per se in early pregnancy for the risk of birth defects 
remains unclarified. A study by Momotani et al. published in 1984 concluded that uncontrolled 
maternal hyperthyroidism may cause congenital malformations and that the beneficial role of 
MMI treatment outweighs its teratogenic risks (30). Only few studies addressed this role of 
maternal hyperthyroidism since then (6,31). We now had the opportunity to investigate the role 
of maternal thyroid function in two independent birth cohorts. The assessment was based on a 
single measurement of TSH and fT4 in a blood sample from early pregnancy, and we 
acknowledge that repeated testing would have been preferred. The overall findings did not 
indicate that abnormal maternal thyroid function was a risk factor for birth defects. This 
observation is in line with the study from Japan (6) in which the authors had access to the review 
of medical records and thereby results of thyroid function testing from women with GD, who 
became pregnant. We observed that maternal overt hypot roidism was a risk factor for birth 
defects in one cohort, and the exposed cases predominantly had malformations of the circulatory 
system. This finding extends a previous case-control s udy in which maternal hypothyroidism 
was associated with congenital heart disease in the offspring (32). These observations encourage 
further investigations and it may be speculated if hypothyroidism secondary to overtreatment of 
maternal hyperthyroidism with ATD could be a risk factor for birth defects. However, we 
observed similar findings when women who received current treatment for thyroid disease at the 
time of blood sampling were excluded from the analyses. The mechanisms by which ATD 
exposure increases the risk of birth defects is not k wn, and the role of thyroid autoimmunity 
per se is intriguing and unclarified. However, in the Danish (7) and Swedish (24) nationwide 
studies we did not see a higher risk of birth defects in women who were diagnosed with 
hyperthyroidism and received no ATD treatment in the pregnancy.  
From a clinical perspective, results of the present tudy corroborates a risk of severe birth 
defects associated with the use of MMI in early pregnancy and supports the use of PTU in early 
pregnancy as put forward in clinical guidance (1,2). Further and large studies are needed to 
investigate the risk associated with PTU and to evaluate outcomes of a shift in therapy. Detailed 
assessment of the timing of exposure up to and after the start of a pregnancy is crucial to inform 
this debate.  
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Figure 1. Flowchart illustrating the selection of the study populations. 
Figure 2. Prevalence of birth defects (all types combined as well as the subtypes previously 
associated with the use of antithyroid drug in early p egnancy) diagnosed before two years of age 
in children live-born in Denmark from 1997 to 2015.  
Table 1 Maternal characteristics in the extended, previous and later Nationwide Register-Based 
Cohort (NRBC), in the Danish National Birth Cohort (DNBC) and in the North Denmark Region 
Pregnancy Cohort (NDRPC) 
 NRBC (extended) NRBC (previous) NRBC (later) DNBC NDRPC 
Pregnancies (n) 1,242,353 771,103 472,250 8,803 14,483 
Birth year of the child 1997-2016 1997-2008 2009-2016 1997-2003 2011-2015 
Maternal characteristics n % n % n % n % n % 
Maternal age            
< 30 years 574,412 46.2 368,977 47.8 205,448 43.5 4,326 49.0 7,520 51.9 
≥ 30 years 668,928 53.8 402,126 52.2 266,802 56.5 4,504 51.0 6,963 48.1 
Maternal parity1           
Nulliparous 550,134 44.8 331,264 43.6 218,870 46.7 4,415 50.0 6,719 46.4 
Multiparous 678,810 55.2 428,654 56.4 250,156 53.3 4,415 50.0 7,761 53.6 
Maternal smoking in 
pregnancy2  
          
No smoking 959,795 84.1 549,024 81.3 410,771 88.3 6,436 72.9 12,789 88.4 
Smoking 180,816 15.9 126,578 18.7 54,238 11.7 2,392 27.1 1,678 11.6 
Maternal pre-pregnancy 
BMI3  
          
< 30 kg/m2 668,213 87.7 265,623 88.4 402,590 87.2 7.963 91.7 12,156 84.0 
≥ 30 kg/m2 93,563 12.3 34,698 11.6 58,865 12.8 724 8.3 2,312 16.0 
Maternal co-morbidity           
No diabetes 1,156,212 93.0 723,104 93.8 433,108 91.7 8,550 96.8 13,183 91.0 
Diabetes 87,141 7.0 47,999 6.2 39,142 8.3 280 3.2 1,300 9.0 
Maternal origin4           
Born in Denmark 1,054,494 84.8 669,121 86.8 385,373 81.7 8,644 97.9 12,838 88.6 
Not born in Denmark 188,508 15.2 101,936 13.2 86,572 18.3 183 2.1 1,645 11.4 
Abbreviations: BMI; body mass index 
1Missing information on parity (n=14,409) not included. 
2Missing information on maternal smoking in pregnancy only available from 1998 onwards, missing information 
(n=102,742) not included. 
3Information on maternal pre-pregnancy BMI only available from 2004 and onwards, missing information 
(n=481,577) not included. 
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Table 2 Frequency of birth defects diagnosed before 2 years of age and corresponding crude 
hazard ratio (cHR) and adjusted hazard ratio (aHR) with 95% confidence intervals (95% CI) 
according to maternal use of antithyroid drug (ATD) in early pregnancy.  
 Children  All birth defects1 Subtypes of birth defects2  
 n n % p3 cHR aHR4 95% CI n % p3 cHR aHR4 95% CI 
Cohort 1997-
2016 
             
Non-exposed5 1,159,181 77,791 6.7 ref. ref. ref.  ref. 35,953 3.1 ref. ref. ref. ref. 










889 74 8.3 0.060 1.25 1.17 0.91-
1.49 




             
Non-exposed5 713,683 41,717 5.9 ref. ref. ref. ref. 19,067 2.7 ref. ref. ref. ref. 










528 47 8.9 0.003 1.55 1.48 1.08-
2.02 
27 5.1 0.001 1.94 1.89 1.26-
2.85 
1ICD-10 diagnoses: Q00-99. 
2ICD-10 diagnoses: Q10-15, Q18, Q20-28, Q30-38, Q39-45, Q60-64, Q79, and Q80-84.  
3p-value is the result of comparison with the non-exposed group using Chi-square test.  
4Adjusted for maternal age, parity, multiple birth, origin, diabetes, and smoking. 
5No diagnosis of hyperthyroidism, no redeemed prescription of antithyroid drugs or Levothyroxine, and no thyroid 
surgery from 1995-2017. 
Table 3 Frequency of subgroups of birth defects diagnosed before 2 years of age in the 
combined NRBC cohort of children born 1997-2016 according to maternal use of antithyroid 
drug (ATD) in early pregnancy.  
 Non-exposed1 Methimazole Propylthiouracil  
 n = 1,159,181 n = 1,574 n = 889 
 n % n2 % p3 n2 % p3 
Subgroups  of birth defects (Q00-99)         
Nervous system (Q00-07) 1,180 0.10 <3 <0.3 0.6 <3 <0.3 0.9 
Eye (Q10-15) 2,480 0.21 7 0.44 0.05 0 0.00 0.2 
Ear (Q16-17) 773 0.07 <3 <0.3 0.4 <3 <0.3 0.07 
Face and neck, others (Q18) 907 0.08 0 0.00 0.3 3 0.34 0.006 
Circulatory system (Q20-28) 15,195 1.31 39 2.48 <0.001 16 1.80 0.2 
Respiratory system (Q30-38) 9,636 0.83 23 1.46 0.006 12 1.35 0.09 
Digestive system (Q39-45) 3,251 0.28 16 1.02 <0.001 <3 <0.3 0.8 
Genital organs (Q50-56) 12,182 1.05 15 0.95 0.7 9 1.01 0.9 
Urinary system (Q60-64) 4,125 0.36 12 0.76 0.007 7 0.79 0.03 
Musculoskeletal system (Q65-78) 29,260 2.52 34 2.16 0.4 26 2.92 0.4 
Muscoloskeletal system, others (Q79) 925 0.08 7 0.44 <0.001 0 0.00 0.4 
Integumentary system (Q80-84) 2,002 0.17 11 0.70 <0.001 <3 <0.3 0.7 
Others (Q85-99) 5,532 0.48 9 0.57 0.6 4 0.45 0.9 
1No diagnosis of hyperthyroidism, no redeemed prescription of antithyroid drugs or Levothyroxine, no thyroid 
surgery 1995-2017. 
2Subgroups with less than three cases were reported as <3 according to the regulations for the use of register-based 
data.   
3p-value is the result of comparison with the non-exposed group using Chi-square test.  
Table 4 Frequency of subtypes of birth defects diagnosed before 2 years of age and the 
associated crude hazard ratio (cHR) and adjusted hazard ratio (aHR) with 95% confidence 
interval (95% CI) according to maternal thyroid function in early pregnancy.  
 Sub-cohort Birth defects1    
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Danish National Birth Cohort (DNBC)        
No thyroid dysfunction 6,673 87.5 1,209 87.4 ref. ref. ref. 
Thyroid dysfunction 951 12.5 174 12.6 1.02 1.02 0.86-1.22 
Hyperthyroidism         
Overt hyperthyroidism 118 1.55 16 1.16 0.75 0.77 0.46-1.30 
Subclinical hyperthyroidism 153 2.01 26 1.88 0.94 0.91 0.60-1.39 
Isolated high free T4 149 1.95 25 1.81 0.95 1.01 0.66-1.55 
Hypothyroidism         
Overt hypothyroidism 55 0.72 19 1.37 1.98 1.91 1.12-3.25 
Subclinical hypothyroidism 302 3.96 53 3.83 0.95 0.95 0.70-1.29 
Isolated low free T4 174 2.28 35 2.53 1.11 1.15 0.79-1.65 
North Denmark Region Pregnancy Cohort (NDRPC)        
No thyroid dysfunction 12,300 84.9 490 84.6 ref. ref. ref. 
Thyroid dysfunction 2,183 15.1 89 15.4 1.03 1.03 0.82-1.30 
Hyperthyroidism         
Overt hyperthyroidism 218 1.51 12 2.07 1.39 1.49 0.84-2.64 
Subclinical hyperthyroidism 330 2.28 10 1.73 0.75 0.79 0.42-1.48 
Isolated high free T4 249 1.72 6 1.04 0.59 0.60 0.27-1.34 
Hypothyroidism         
Overt hypothyroidism 145 1.00 5 0.86 0.86 0.86 0.36-2.09 
Subclinical hypothyroidism 752 5.19 33 5.70 1.11 1.08 0.76-1.53 
Isolated low free T4 489 3.89 23 3.97 1.19 1.19 0.79-1.82 
1ICD-10 diagnoses: Q10-15, Q18, Q20-28, Q30-38, Q39-45, Q60-64, Q79, and Q80-84.  
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